Key takeaways:
- Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule
- The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter
